Psychopathological symptoms of patients with heroin addiction entering opioid agonist or therapeutic community treatment

Annals of General Psychiatry

Volumn 13, Issue 1, 2014, Pages

  Pani, Paolo ^a   Trogu, Emanuela ^a   Vigna Taglianti, Federica ^b,c   Mathis, Federica ^b   Diecidue, Roberto ^b   Kirchmayer, Ursula ^d   Amato, Laura ^d   Davoli, Marina ^d   Ghibaudi, Joli ^e   Camposeragna, Antonella ^e   Saponaro, Alessio ^f   Faggiano, Fabrizio ^g   Maremmani, Icro ^h,h,i,i,j  

^a Territorial Department of Nephrology and Dialysis   (Italy)

^b Piedmont Centre for Drug Addiction Epidemiology   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d DEPARTMENT OF EPIDEMIOLOGY   (Italy)

^e National Coordination Hospitality Communities (CNCA)   (Italy)

^f Regional Epidemiologic Observatory Emilia Romagna Regional Health Service   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h UNIVERSITY HOSPITAL OF PISA   (Italy)

ⁱ Association for the Application of Neuroscientific Knowledge to Social Aims AU CNS   (Italy)

^j G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

more..

Author keywords

Gender differences; Opioid agonist treatment; Psychopathological symptoms; Residential treatment community; SCL 90

Indexed keywords

DIAMORPHINE; OPIATE AGONIST;

ADULT; ANXIETY DISORDER; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DEPENDENCE TREATMENT; EDUCATIONAL STATUS; EMPLOYMENT STATUS; FEMALE; HEROIN DEPENDENCE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MENTAL DISEASE; OUTPATIENT CARE; PANIC; PSYCHOSIS; RESIDENTIAL CARE; SEX RATIO; SOCIAL WELFARE; SOMATIZATION; SUICIDE; SYMPTOM CHECKLIST 90; THERAPEUTIC COMMUNITY; VIOLENCE;

EID: 84924226826     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-014-0035-x     Document Type: Article

References (75)

1. A.P.A: Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 5th edition. Washington, D.C: American Psychiatric Association; 2013.
2. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. JAMA 1990, 19(264):2511-2518.
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS: Lifetime and 12-month prevalence of DSM-IIIR psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
4. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W, Pickering RP, Kaplan K: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry 2004, 61:807-816.
5. Verheul R, Kranzler HR, Poling J, Tennen H, Ball S, Rounsaville BJ: Axis I and Axis II disorders in alcoholics and drug addicts: fact or artifact? J Stud Alcohol 2000, 61:101-110.
6. Volkow ND, Fowler JS, Wang GJ: Role of dopamine in drug reinforcement and addiction in humans: results from imaging studies. Behav Pharmacol 2002, 13:355-366.
7. Goldstein RZ, Volkow ND: Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002, 159:1642-1652.
8. Brook DW, Brook JS, Zhang C, Cohen P, Whiteman M: Drug use and the risk of major depressive disorder, alcohol dependence, and substance use disorders. Arch Gen Psychiatry 2002, 59:1039-1044.
9. Volkow ND, Fowler JS, Wang GJ, Swanson JM: Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004, 9:557-569.
10. Brady KT, Sinha R: Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry 2005, 162:1483-1493.
11. Cuthbert BN: The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 2014, 13:28-35.
12. Maremmani I, Perugi G, Pacini M, Akiskal HS: Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006, 93:1-12.
13. Pani PP, Maremmani I, Trogu E, Gessa GL, Ruiz P, Akiskal HS: Delineating the psychic structure of substance abuse and addictions: should anxiety, mood and impulse-control dysregulation be included? J Affect Disord 2010, 122:185-197.
14. Ross HE, Swinson R, Doumani S, Larkin EJ: Diagnosing comorbidity in substance abusers: a comparison of the test-retest reliability of two interviews. Am J Drug Alcohol Abuse 1995, 21:167-185.
15. Kranzler HR, Kadden RM, Burleson JA, Babor TF, Apter A, Rounsaville BJ: Validity of psychiatric diagnoses in patients with substance use disorders: is the interview more important than the interviewer? Compr Psychiatry 1995, 36:278-288.
16. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J: Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996, 153:1195-1201.
17. Samet S, Nunes EV, Hasin DS: Diagnosing comorbidity: concepts, criteria, and methods. Acta Neuropsychiatr 2004, 16:9-18.
18. Hasin D, Samet S, Nunes E, Meydan J, Matseoane K, Waxman R: Diagnosis of comorbid psychiatric disorders in substance users assessed with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry 2006, 163:689-696.
19. Carpenter KM, Hittner JB: Dimensional characteristics of the SCL-90-R: evaluation of gender differences in dually diagnosed inpatients. J Clin Psychol 1995, 51:383-390.
20. Zack M, Toneatto T, Streiner DL: The SCL-90 factor structure in comorbid substance abusers. J Subst Abuse 1998, 10:85-101.
21. Maremmani I, Pacini M, Pani PP, Perugi G, Deltito J, Akiskal H: The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a 'dual diagnosis'? Ann Gen Psychiatry 2007, 6:31.
22. Maremmani I, Pani PP, Pacini M, Bizzarri JV, Trogu E, Maremmani AGI, Perugi G, Gerra G, Dell'Osso L: Subtyping patients with heroin addiction at treatment entry: factors derived from the SCL-90. Ann Gen Psychiatry 2010, 9:15.
23. Mathis F, Vigna-Taglianti F, Decidue R, Kirchmayer U, Piras G, Amato L, Ghibaudi J, Camposeragna A, Saponaro A, Faggiano F, Trogu E, Pani PP: Studio "Valutazione dell'Offerta e dell'Esito dei trattamenti in Comunità Terapeutiche (VOECT), Ministero della Salute, Ricerca finalizzata. Monografia n. 1, Analisi descrittiva della coorte arruolata. Cagliari: Centro Stampa Regione Sardegna; 2013.
24. Derogatis LR, Lipman RS, Rickels K: The Hopkins Symptom Checklist (HSCL): a self report symptom inventory. Behav Sci 1974, 19:1-16.
25. Landis JR, Koch GG: The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174.
26. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, Lubar JO, Chen TJ, Comings DE: Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors. J Psychoactive Drugs 2000, 32:1-112.
27. Schuckit MA, Tipp JE, Bucholz KK, Nurnberger JI, Hesselbrock Crowe RR, Kramer J: The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 1997, 92:1289-1304.
28. Gerra G, Angioni L, Zaimovic A, Moi G, Bussandri M, Bertacca S, Santoro G, Gardini S, Caccavari R, Nicoli MA: Substance use among high-school students: relationships with temperament, personality traits, and parental care perception. Subst Use Misuse 2004, 39:345-367.
29. Camacho A, Akiskal HS: Proposal for a bipolar-stimulant spectrum: temperament, diagnostic validation and therapeutic outcomes with mood stabilizers. J Affect Disord 2005, 85:217-230.
30. Conner KR, Sörensen S, Leonard KE: Initial depression and subsequent drinking during alcoholism treatment. J Stud Alcohol 2005, 66:401-406.
31. Volman SF, Lammel S, Margolis EB, Kim Y, Richard JM, Roitman MF, Lobo MK: New insights into the specificity and plasticity of reward and aversion encoding in the mesolimbic system. J Neurosci 2013, 33:17569-17576.
32. Post RM, Kalivas P: Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry 2013, 202:172-176.
33. Shippenberg TS, Zapata A, Chefer VI: Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 2007, 116:306-321.
34. Heilig M, Egli M, Crabbe JC, Becker HC: Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked? Addict Biol 2010, 15:169-184.
35. Logrip ML, Koob GF, Zorrilla EP: Role of corticotropin-releasing factor in drug addiction: potential for pharmacological intervention. CNS Drugs 2011, 25:271-287.
36. Maremmani I, Pacini M, Pani PP, Popovic D, Romano A, Maremmani AG, Deltito J, Perugi G: Use of street methadone in Italian heroin addicts presenting for opioid agonist treatment. J Addict Dis 2009, 28:382-388.
37. Maremmani AGI, Rovai L, Pani PP, Pacini M, Lamanna F, Rugani F, Schiavi E, Dell'Osso L, Maremmani I: Do methadone and buprenorphine have the same impact on psychopathological symptoms of heroin addicts? Ann Gen Psychiatry 2011, 10:17.
38. Deglon JJ, Wark E: Methadone: a fast and powerful anti-anxiety, anti-depressant and anti-psychotic treatment. Heroin Addict Relat Clin Probl 2008, 10:49-56.
39. Pacini M, Maremmani I: Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and/or acute psychotic episodes. Heroin Addict Relat Clin Probl 2005, 7:43-48.
40. Schmauss C, Yassouridis A, Emrich HM: Antipsychotic effect of buprenorphine in schizophrenia. Am J Psychiatry 1987, 144:1340-1342.
41. Clouet DH: A biochemical and neurophysiological comparison of opioids and antipsychotics. Ann NY Acad Sci 1982, 398:130-139.
42. Gold MS, Donabedian RK, Dillard MJ, Slobetz FW, Riordan CE, Kleber HD: Antipsychotic effect of opiate agonists. Lancet 1977, 20:398-399.
43. Levinson I, Galynker II, Rosenthal RN: Methadone withdrawal psychosis. J Clin Psychiatry 1995, 56:73-76.
44. Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, Lieberman JA, Bracha SH, Ali SF: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry 1999, 4:512-523.
45. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C: Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 2006, 63:1386-1395.
46. Kalayasiri R, Kranzler HR, Weiss R, Brady K, Gueorguieva R, Panhuysen C, Yang BZ, Farrer L, Gelernter J, Malison RT: Risk factors for cocaine-induced paranoia in cocaine-dependent sibling pairs. Drug Alcohol Depend 2006, 84:77-84.
47. Thomas H: A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996, 42:201-207.
48. Chaudry HR, Moss HB, Bashir A, Suliman T: Cannabis psychosis following bhang ingestion. Br J Addict 1991, 86:1075-1081.
49. Solomons K, Neppe VM, Kuyl JM: Toxic cannabis psychosis is a valid entity. S Afr Med J 1990, 78:476-481.
50. Wylie AS, Scott RTA, Burnett SJ: Psychosis due to 'skunk'. BMJ 1995, 311:125.
51. Hall W, Degenhardt L, Teesson M: Cannabis use and psychotic disorders: an update. Drug Alcohol Rev 2004, 23:433-443.
52. Burns JK: Pathways from cannabis to psychosis: a review of the evidence. Front Psychiatry 2013, 4:128.
53. Bacciardi S, Maremmani AGI, Rovai L, Rugani F, Pani PP, Pacini M, Dell'Osso L, Akiskal HS, Maremmani I: Drug (heroin) addiction, bipolar spectrum and impulse control disorders. Heroin Addict Relat Clin Probl 2013, 15:29-36.
54. Kathleen Holmes M, Bearden CE, Barguil M, Fonseca M, Serap Monkul E, Nery FG, Soares JC, Mintz J, Glahn DC: Conceptualizing impulsivity and risk taking in bipolar disorder: importance of history of alcohol abuse. Bipolar Disord 2009, 11:33-40.
55. Maremmani I, Pacini M, Perugi G: Addictive disorders, bipolar spectrum and the impulsive link: the psychopathology of a self-regenerating pathway. Heroin Addict Relat Clin Probl 2005, 7:33-46.
56. Madden GJ, Petry NM, Badger GJ, Bickel WK: Impulsive and self-control choices in opioid-dependent patients and non-drug-using control participants: drug and monetary rewards. Exp Clin Psychopharmacol 1997, 5:256-262.
57. Petry NM: Discounting of money, health, and freedom in substance abusers and controls. Drug Alcohol Depend 2003, 71:133-141.
58. Nigg JT, Wong MM, Martel MM, Jester JM, Puttler LI, Glass JM, Adams KM, Fitzgerald HE, Zucker RA: Poor response inhibition as a predictor of problem drinking and illicit drug use in adolescents at risk for alcoholism and other substance use disorders. J Am Acad Child Adolesc Psychiatry 2006, 45:468-475.
59. Kirisci L, Tarter RE, Reynolds M, Vanyukov M: Individual differences in childhood neurobehavior disinhibition predict decision to desist substance use during adolescence and substance use disorder in young adulthood: a prospective study. Addict Behav 2006, 31:686-696.
60. Baldacchino A, Balfour DJ, Passetti F, Humphris G, Matthews K: Neuropsychological consequences of chronic opioid use: a quantitative review and meta-analysis. Neurosci Biobehav Rev 2012, 36:2056-2068.
61. Nielsen DA, Kreek MJ: Common and specific liability to addiction: approaches to association studies of opioid addiction. Drug Alcohol Depend 2012, 123(Suppl 1):S33-S41.
62. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P: Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2003, 3:CD002208.
63. Mattick RP, Kimber J, Breen C, Davoli M: Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008, 2:CD002207.
64. WHO: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence, www.who.int/substance:abuse/publications/opioid_dependence:guidelines.pdf. Geneva: WHO; 2009. Accessed on September 21, 2014.
65. Broekaert E, Vandevelde S, Soyez V, Yates R, Slater A: The third generation of therapeutic communities: the early development of the TC for addictions in Europe. Eur Addict Res 2006, 12:1-11.
66. Melnick G, De Leon G, Hiller ML, Knight K: Therapeutic communities: diversity in treatment elements. Subst Use Misuse 2000, 35:1819-1847.
67. Dye MH, Ducharme LJ, Johnson JA, Knudsen HK, Roman PM: Modified therapeutic communities and adherence to traditional elements. J Psychoactive Drugs 2009, 41:275-283.
68. Vanderplasschen W, Colpaert K, Autrique M, Rapp RC, Pearce S, Broekaert E, Vandevelde S: Therapeutic communities for addictions: a review of their effectiveness from a recovery-oriented perspective. Scientific World Journal 2013, 2013:427817.
69. Murphy A, Taylor E, Elliott R: The detrimental effects of emotional process dysregulation on decision-making in substance dependence. Front Integr Neurosci 2012, 6:101.
70. Bari A, Robbins TW: Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol 2013, 108:44-79.
71. Kosten TR, Rounsaville BJ, Kleber HD: Ethnic and gender differences among opiate addicts. Int J Addict 1985, 20:1143-1162.
72. Green TC, Grimes Serrano JM, Licari A, Budman SH, Butler SF: Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend 2009, 103:65-73.
73. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R: The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005, 24:411-418.
74. Teesson M, Havard A, Fairbairn S, Ross J, Lynskey M, Darke S: Depression among entrants to treatment for heroin dependence in the Australian Treatment Outcome Study (ATOS): prevalence, correlates and treatment seeking. Drug Alcohol Depend 2005, 78:309-315.
75. Back SE, Payne RL, Wahlquist AH, Carter RE, Stroud Z, Haynes L, Hillhouse M, Brady KT, Ling W: Comparative profiles of men and women with opioid dependence: results from a national multisite effectiveness trial. Am J Drug Alcohol Abuse 2011, 37:313-323.